Subjects have other endocrine diseases, such as adrenal hyperplasias or tumor, androgen-secreting tumors, Cushing's syndrome, thyroid diseases, and hyperprolactinemia
Diagnosed with or have a family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Serious systemic disease or malignant tumor
History of pancreatitis (chronic, acute or recurrent)
Body weight change ≥10% at 3 months before treatment
Used oral contraceptives or sex hormone drugs in the past 1 month
Used oral glucocorticoids in the past 1 month
Substance (alcohol or drug) abuse or dependence within 3 months; Heavy smokers (smokers who smoke 20 or more cigarettes a day) or heavy drinkers (\>10g/d)
Subjects have a severe systemic disease, such as cardiovascular system
Renal impairment, eGFR\<60ml/min/1.73m2
Increase of transaminases up to \< 2.5 times of upper limit of normal value
Have a history of thromboembolic disease or thrombotic tendency
Subjects in pregnant or lactating or within 1 year after delivery.
Subjects have an allergic history to the drugs used in the study
Subjects have participated in other clinical researches of medicine within 1 month prior to randomization.
Use of metformin, glucagon-like peptide -1 receptor agonists, or weight loss medications (prescription or OTC) within 30 days before screening.
Clareo Health | Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients
